GlaxoSmithKline Inc. releases statement applauding federal government’s vaccine contract
by CM Staff
The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic.
GSK Canada Sainte-Foy Production Facility (CNW Group/GlaxoSmithKline Inc.)
SAINTE-FOY — On Jul. 15, GSK announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine). Both vaccines will be supplied by GSK’s Sainte-Foy, Quebec facility. This agreement follows earlier agreements between the Government of Canada and GSK to supply both pandemic and seasonal influenza vaccines dating back to 2001.
Jean-Yves Duclos, Minister of Health, mentions: “An influenza pandemic can be caused by a new influenza strain against which there is little or no pre-existing immunity in the population. As these pandemics are unpredictable, and have at times caused severe disease, even death, in the population, it is of the utmost importance to the Government of Canada to be prepared to protect Canadians. With today’s announcement, we are increasing pandemic preparedness, and supporting quality jobs as these vaccines will be produced at GSK’s Sainte-Foy, Quebec, facility.”
Roger Connor, President of GSK Vaccines, said: “We are proud to continue to work with the Government of Canada to supply our vaccines, supporting Canada’s pandemic preparedness and fight against seasonal influenza. COVID-19 has shown the world the importance of immunization and pandemic preparedness. This agreement reserves future production and delivery of pandemic and seasonal influenza vaccines allowing for a rapid response to help protect Canadians.”
GSK’s pandemic influenza vaccine, Arepanrix, is composed of a monovalent, inactivated, strain of the influenza virus antigen and GSK’s pandemic adjuvant system.
GSK’s seasonal influenza vaccine, Flulaval Tetra, is a quadrivalent vaccine (split virion, inactivated) indicated for active immunization of adults and children from 6 months of age for the prevention of influenza disease caused by influenza virus types A and B contained in the vaccine.
“Today’s announcement continues the longstanding relationship between the Government of Canada and GSK to provide a domestic supply of influenza vaccines,” says Peter Fonyodi, Vaccines Business Unit Head, GSK Canada. “I’m particularly proud that these vaccines will come from our 230,000 square foot Sainte-Foy, Quebec production facility.”
GSK is a manufacturer of biopharmaceutical products and vaccines, as well as pandemic preparedness and response.
